Exact Mass: 654.3463

Exact Mass Matches: 654.3463

Found 278 metabolites which its exact mass value is equals to given mass value 654.3463, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

all-trans-Heptaprenyl diphosphate

[({[(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl]oxy}(hydroxy)phosphoryl)oxy]phosphonic acid

C35H60O7P2 (654.3814)


all-trans-Heptaprenyl diphosphate is the final product of the heptaprenyl diphosphate biosynthesis pathway. In this pathway, multiple units of isopentenyl diphosphate (IPP) undergo a series of polymerizations to form a polyisoprenoid chain. The sequential addition of isoprenyl units to all-trans-farnesyl diphosphate is performed by polyprenyl diphosphate synthase enzymes such as the E. coli enzyme octaprenyl diphosphate synthase. Additional isoprenoid units are added to a maximal length that is determined by the specific enzyme. Most organisms generate polyprenyl chains of predominantly one length. Once completed, the polyprenyl chain is incorporated into other molecules, such as quinones. The enzyme that attaches the polyprenyl chain to the quinone precursor molecule does not have a preference for any particular length. Thus, the length of the polyprenyl chain in the mature quinone molecule is determined by the predominant polyprenyl diphosphate synthase enzyme of the organism. In most organisms, there is one type of predominant quinone, with a specific polyprenyl chain length. However, most organisms also have minor amounts of quinones with a different polyprenyl chain length. Organisms whose main quinone contains a chain of 7 isoprenyl units include some Gram-negative bacteria (e.g. the gliding bacterium Flexibacter elegans and the phototroph Allochromatium vinosum strain D), but mostly Gram-positive bacteria, such as many members of the Bacillus, Staphylococcus, and Listeria genera. All-trans-heptaprenyl diphosphate is the final product of heptaprenyl diphosphate biosynthesis pathway.In this pathway multiple units of isopentenyl diphosphate (IPP) undergo a series of polymerizations to form a polyisoprenoid chain.

   

ditrans,tetracis-Heptaprenyl diphosphate

ditrans,tetracis-Heptaprenyl diphosphate

C35H60O7P2 (654.3814)


   

Argenteane

4-[3-(2H-1,3-benzodioxol-5-ylmethyl)-2-methylbutyl]-2-{5-[3-(2H-1,3-benzodioxol-5-ylmethyl)-2-methylbutyl]-2-hydroxy-3-methoxyphenyl}-6-methoxyphenol

C40H46O8 (654.3193)


Argenteane is found in herbs and spices. Argenteane is a constituent of mace, Myristica argentea. Constituent of mace, Myristica argentea. Argenteane is found in herbs and spices.

   

PA(12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-3-(dodecanoyloxy)-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(12:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:4(6E,8Z,11Z,14Z)+=O(5)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/12:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(12:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:4(5Z,8Z,11Z,13E)+=O(15)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/12:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/12:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/12:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/12:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-3-(dodecanoyloxy)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/12:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

[(2R)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

[(2R)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H59O9P (654.3896)


PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   

Sordarin-1-glucose ester

Sordarin-1-glucose ester

C33H50O13 (654.3251)


   

Moluccensin B

Moluccensin B

C36H46O11 (654.304)


   

Moluccensin C

Moluccensin C

C36H46O11 (654.304)


   

Chisonimbolinin C

Chisonimbolinin C

C37H50O10 (654.3404)


   
   

gyroxanthal 3 acetate

gyroxanthal 3 acetate

C42H54O6 (654.392)


   

14beta-(8(14),9(11)-diene-18alpha-methoxycarbonyl-18-norvouacapen-16-yl)-18alpha-methoxycarbonyl-18-norvouacapene|mimosol E

14beta-(8(14),9(11)-diene-18alpha-methoxycarbonyl-18-norvouacapen-16-yl)-18alpha-methoxycarbonyl-18-norvouacapene|mimosol E

C42H54O6 (654.392)


   

sarmentogenin-3-O-)-beta-D-ribopyranoside>|sarmentogenin-3-O-[beta-D-xylopyranosyl-(1->)-beta-D-ribopyranoside]

sarmentogenin-3-O-)-beta-D-ribopyranoside>|sarmentogenin-3-O-[beta-D-xylopyranosyl-(1->)-beta-D-ribopyranoside]

C33H50O13 (654.3251)


   
   

bispuupehenone

bispuupehenone

C42H54O6 (654.392)


   

3-deacetyl-3-hydroxy-fusicoccin A|fusicoccin R

3-deacetyl-3-hydroxy-fusicoccin A|fusicoccin R

C34H54O12 (654.3615)


   

(1alpha,6beta,14alpha,16beta)-1,6,14,16-tetramethoxy-4-{{[2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoyl]oxy}methyl}aconitane-7,8-diol|N-deethylmethyllylcaconitine

(1alpha,6beta,14alpha,16beta)-1,6,14,16-tetramethoxy-4-{{[2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoyl]oxy}methyl}aconitane-7,8-diol|N-deethylmethyllylcaconitine

C35H46N2O10 (654.3152)


   
   
   

MCULE-4499116446

MCULE-4499116446

C31H58O14 (654.3826)


   
   

solanolactoside A

solanolactoside A

C34H54O12 (654.3615)


   

neobonaspectin A

neobonaspectin A

C36H46O11 (654.304)


   

15-((3aXi,11bR)-8,11c-dihydroxy-3-methyl-6-oxo-(11cc)-2,3,3a,5,6,11c-hexahydro-1H,4H-indolo[3,2,1-de][1,5]naphthyridin-11br-yl)-19-hydroxy-16,17-dimethoxy-1-methyl-3,4-didehydro-aspidospermidin-21-oic acid 19-lactone|Cimiciphytin|cimiciphytine

15-((3aXi,11bR)-8,11c-dihydroxy-3-methyl-6-oxo-(11cc)-2,3,3a,5,6,11c-hexahydro-1H,4H-indolo[3,2,1-de][1,5]naphthyridin-11br-yl)-19-hydroxy-16,17-dimethoxy-1-methyl-3,4-didehydro-aspidospermidin-21-oic acid 19-lactone|Cimiciphytin|cimiciphytine

C37H42N4O7 (654.3053)


   

moluccensin K

moluccensin K

C36H46O11 (654.304)


   

dipuupehetriol

dipuupehetriol

C42H54O6 (654.392)


   

14-demethyllycaconitine

14-demethyllycaconitine

C35H46N2O10 (654.3152)


   
   
   
   

Antibiotic T23VI

Antibiotic T23VI

C36H50N2O9 (654.3516)


   

Methyllycaconitine

Methyllycaconitine

C35H46N2O10 (654.3152)


   

pololohuanone E

pololohuanone E

C42H54O6 (654.392)


   

Lys His Ile Glu Glu

Lys His Ile Glu Glu

C28H46N8O10 (654.3337)


   

Ile Glu Tyr Cys Lys

Ile Glu Tyr Cys Lys

C29H46N6O9S (654.3047)


   

C37H50O10_2-Butenoic acid, 2-methyl-, 5-(acetyloxy)-8-(3-furanyl)hexadecahydro-1,1,5a,7a,10b-pentamethyl-7-(2-methyl-1-oxopropoxy)-3-oxooxireno[1,5]cyclopenta[1,2:5,6]naphth[2,1-c]oxepin-11-yl ester, (2E)

NCGC00380573-01_C37H50O10_2-Butenoic acid, 2-methyl-, 5-(acetyloxy)-8-(3-furanyl)hexadecahydro-1,1,5a,7a,10b-pentamethyl-7-(2-methyl-1-oxopropoxy)-3-oxooxireno[1,5]cyclopenta[1,2:5,6]naphth[2,1-c]oxepin-11-yl ester, (2E)-

C37H50O10 (654.3404)


   
   
   

Phe Phe Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C35H42N8O5 (654.3278)


   

Phe Phe Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C35H42N8O5 (654.3278)


   

Phe Arg Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C35H42N8O5 (654.3278)


   

Phe Arg Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C35H42N8O5 (654.3278)


   

Phe Trp Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C35H42N8O5 (654.3278)


   

Phe Trp Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C35H42N8O5 (654.3278)


   

Arg Phe Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C35H42N8O5 (654.3278)


   

Arg Phe Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C35H42N8O5 (654.3278)


   

Arg Trp Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C35H42N8O5 (654.3278)


   

Trp Phe Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C35H42N8O5 (654.3278)


   

Trp Phe Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C35H42N8O5 (654.3278)


   

Trp Arg Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C35H42N8O5 (654.3278)


   

IEYCK

Ile-Glu-Tyr-Cys-Lys

C29H46N6O9S (654.3047)


   

KHIEE

Lys His Ile Glu Glu

C28H46N8O10 (654.3337)


   

PI(22:1(11Z)/0:0)

1-(11Z-docosenoyl)-glycero-3-phospho-(1-myo-inositol)

C31H59O12P (654.3744)


   

Argenteane

4-[4-(2H-1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-{5-[3-(2H-1,3-benzodioxol-5-ylmethyl)-2-methylbutyl]-2-hydroxy-3-methoxyphenyl}-6-methoxyphenol

C40H46O8 (654.3193)


   

DGMG 16:0

1-palmitoyl-3-O-(6-O-alpha-D-galactopyranosyl-beta-D-galactopyranosyl)-sn-glycerol

C31H58O14 (654.3826)


   

LPI 22:1

1-(11Z-docosenoyl)-glycero-3-phospho-(1-myo-inositol)

C31H59O12P (654.3744)


   

PHODiA-PG

1-hexadecanoyl-2-(5-hydroxy-7-carboxy-6E-heptenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C30H55O13P (654.338)


   

PA-PG

1-hexadecanoyl-2-azeloyl-sn-glycero-3-phospho-(1-sn-glycerol)

C31H59O12P (654.3744)


   

Stelleracin D

12-O-benzoyl-13-O-decanoyl-7beta-hydroperoxy-6,7-dihydrophorbol-5-ene

C37H50O10 (654.3404)


   

All-trans-heptaprenyl diphosphate

(2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl trihydrogen diphosphate

C35H60O7P2 (654.3814)


An all-trans-polyprenyl diphosphate composed from seven isoprenyl units.

   

TRIISOPROPYL((4-((4-((4-((4-((TRIMETHYLSILYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)SILANE

TRIISOPROPYL((4-((4-((4-((4-((TRIMETHYLSILYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)SILANE

C46H46Si2 (654.3138)


   

Atorvastatin Acetonide tert-Butyl Ester

Atorvastatin Acetonide tert-Butyl Ester

C40H47FN2O5 (654.3469)


   
   

[(2Z,6Z,10Z,14Z,18Z,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaenyl] phosphono hydrogen phosphate

[(2Z,6Z,10Z,14Z,18Z,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaenyl] phosphono hydrogen phosphate

C35H60O7P2 (654.3814)


   

PA(12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C35H59O9P (654.3896)


   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/12:0)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/12:0)

C35H59O9P (654.3896)


   

PA(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C35H59O9P (654.3896)


   

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

C35H59O9P (654.3896)


   

PA(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

PA(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C35H59O9P (654.3896)


   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

C35H59O9P (654.3896)


   

PA(12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

PA(12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C35H59O9P (654.3896)


   

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/12:0)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/12:0)

C35H59O9P (654.3896)


   

PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C35H59O9P (654.3896)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/12:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/12:0)

C35H59O9P (654.3896)


   

PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PA(12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C35H59O9P (654.3896)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/12:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/12:0)

C35H59O9P (654.3896)


   

PA(12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PA(12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C35H59O9P (654.3896)


   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/12:0)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/12:0)

C35H59O9P (654.3896)


   

PA(12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PA(12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C35H59O9P (654.3896)


   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/12:0)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/12:0)

C35H59O9P (654.3896)


   

PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C35H59O9P (654.3896)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

C35H59O9P (654.3896)


   

PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PA(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C35H59O9P (654.3896)


   

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

C35H59O9P (654.3896)


   

PA(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PA(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C35H59O9P (654.3896)


   

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

C35H59O9P (654.3896)


   

PA(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PA(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C35H59O9P (654.3896)


   

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

C35H59O9P (654.3896)


   

Euphorbiaproliferin I

Euphorbiaproliferin I

C36H46O11 (654.304)


A natural product found in Euphorbia prolifera.

   

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-docos-13-enoate

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-docos-13-enoate

C31H59O12P (654.3744)


   

Dgdg O-9:0_7:0

Dgdg O-9:0_7:0

C31H58O14 (654.3826)


   

Dgdg O-8:0_8:0

Dgdg O-8:0_8:0

C31H58O14 (654.3826)


   

Smgdg O-20:1_2:0

Smgdg O-20:1_2:0

C31H58O12S (654.3649)


   

Smgdg O-17:1_5:0

Smgdg O-17:1_5:0

C31H58O12S (654.3649)


   

Smgdg O-16:1_6:0

Smgdg O-16:1_6:0

C31H58O12S (654.3649)


   

Smgdg O-15:1_7:0

Smgdg O-15:1_7:0

C31H58O12S (654.3649)


   

Smgdg O-13:1_9:0

Smgdg O-13:1_9:0

C31H58O12S (654.3649)


   

Smgdg O-19:1_3:0

Smgdg O-19:1_3:0

C31H58O12S (654.3649)


   

Smgdg O-9:0_13:1

Smgdg O-9:0_13:1

C31H58O12S (654.3649)


   

Smgdg O-8:0_14:1

Smgdg O-8:0_14:1

C31H58O12S (654.3649)


   

Smgdg O-14:1_8:0

Smgdg O-14:1_8:0

C31H58O12S (654.3649)


   

Smgdg O-18:1_4:0

Smgdg O-18:1_4:0

C31H58O12S (654.3649)


   

Dgdg O-11:0_5:0

Dgdg O-11:0_5:0

C31H58O14 (654.3826)


   

Dgdg O-14:0_2:0

Dgdg O-14:0_2:0

C31H58O14 (654.3826)


   

Dgdg O-12:0_4:0

Dgdg O-12:0_4:0

C31H58O14 (654.3826)


   

Dgdg O-10:0_6:0

Dgdg O-10:0_6:0

C31H58O14 (654.3826)


   

Dgdg O-13:0_3:0

Dgdg O-13:0_3:0

C31H58O14 (654.3826)


   

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C34H55O10P (654.3533)


   

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate

[1-Hexanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate

C30H54O15 (654.3463)


   

[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] octanoate

[1-Heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] octanoate

C30H54O15 (654.3463)


   

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] undecanoate

C30H54O15 (654.3463)


   

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] decanoate

C30H54O15 (654.3463)


   

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] dodecanoate

C30H54O15 (654.3463)


   

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tridecanoate

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] tridecanoate

C30H54O15 (654.3463)


   

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate

C30H55O13P (654.338)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

C30H55O13P (654.338)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-octadec-9-enoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-octadec-9-enoate

C30H55O13P (654.338)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C34H55O10P (654.3533)


   

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate

[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate

C30H55O13P (654.338)


   

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-heptadec-9-enoate

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-heptadec-9-enoate

C30H55O13P (654.338)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-tridec-9-enoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-tridec-9-enoate

C30H55O13P (654.338)


   

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-nonadec-9-enoate

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-nonadec-9-enoate

C30H55O13P (654.338)


   

[(2S,3S,6S)-6-[(2S)-2,3-di(undecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-2,3-di(undecanoyloxy)propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C31H58O12S (654.3649)


   

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C31H58O12S (654.3649)


   

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[(2S)-2-decanoyloxy-3-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C31H58O12S (654.3649)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C34H55O10P (654.3533)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C34H55O10P (654.3533)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C34H55O10P (654.3533)


   

1-palmitoyl-2-azeloyl-sn-glycero-3-phospho-(1-sn-glycerol)

1-palmitoyl-2-azeloyl-sn-glycero-3-phospho-(1-sn-glycerol)

C31H59O12P (654.3744)


   

1-(11Z-docosenoyl)-glycero-3-phospho-(1-myo-inositol)

1-(11Z-docosenoyl)-glycero-3-phospho-(1-myo-inositol)

C31H59O12P (654.3744)


   

heptaprenyl diphosphate

heptaprenyl diphosphate

C35H60O7P2 (654.3814)


A polyprenol diphosphate compound having seven prenyl units with undefined stereochemistry about the double bonds.

   
   
   
   
   
   
   

PA 18:2/13:4;O2

PA 18:2/13:4;O2

C34H55O10P (654.3533)


   

PA 18:3/13:3;O2

PA 18:3/13:3;O2

C34H55O10P (654.3533)


   

PA 18:4/12:3;O3

PA 18:4/12:3;O3

C33H51O11P (654.3169)


   

PA 20:2/12:3;O

PA 20:2/12:3;O

C35H59O9P (654.3896)


   
   
   
   
   
   
   
   

PG O-18:0/7:2;O3

PG O-18:0/7:2;O3

C31H59O12P (654.3744)


   
   

PG 16:0/8:2;O3

PG 16:0/8:2;O3

C30H55O13P (654.338)


   
   
   
   
   
   
   
   
   
   
   
   

PI P-16:0/5:1;O

PI P-16:0/5:1;O

C30H55O13P (654.338)


   

PI P-16:1/4:1;O2

PI P-16:1/4:1;O2

C29H51O14P (654.3016)


   
   

PI P-18:0/4:0 or PI O-18:1/4:0

PI P-18:0/4:0 or PI O-18:1/4:0

C31H59O12P (654.3744)


   
   

PI P-20:0/2:0 or PI O-20:1/2:0

PI P-20:0/2:0 or PI O-20:1/2:0

C31H59O12P (654.3744)


   
   

PI P-22:0 or PI O-22:1

PI P-22:0 or PI O-22:1

C31H59O12P (654.3744)


   
   
   
   
   
   
   
   
   
   
   

ST 27:3;O7;GlcA

ST 27:3;O7;GlcA

C33H50O13 (654.3251)


   

ST 28:2;O6;GlcA

ST 28:2;O6;GlcA

C34H54O12 (654.3615)


   

ST 27:4;O8;Hex

ST 27:4;O8;Hex

C33H50O13 (654.3251)


   

ST 28:3;O7;Hex

ST 28:3;O7;Hex

C34H54O12 (654.3615)


   

10,11,22-trihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-12-yl benzoate

10,11,22-trihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-12-yl benzoate

C37H50O10 (654.3404)


   

6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-5-yl deca-2,4-dienoate

6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-5-yl deca-2,4-dienoate

C37H50O10 (654.3404)


   

(1r,2s,5r,6r,13s,14s,15s,17s,18s)-6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl (2s)-2-methylbutanoate

(1r,2s,5r,6r,13s,14s,15s,17s,18s)-6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl (2s)-2-methylbutanoate

C36H46O11 (654.304)


   

[5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl deca-2,4-dienoate

[5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl deca-2,4-dienoate

C37H50O10 (654.3404)


   

(1r,2r,4s,5s,6s,7s,8r,9s,10s,11r,13s,15r,17r)-6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-5-yl (2e,4e)-deca-2,4-dienoate

(1r,2r,4s,5s,6s,7s,8r,9s,10s,11r,13s,15r,17r)-6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-5-yl (2e,4e)-deca-2,4-dienoate

C37H50O10 (654.3404)


   

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C35H46N2O10 (654.3152)


   

(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

C29H46N6O9S (654.3047)


   

(1s,2r,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-2-methylbut-2-enoate

(1s,2r,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-2-methylbut-2-enoate

C36H46O11 (654.304)


   

n-(4-carbamimidamidobutyl)-1-(2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl)-6-(sulfooxy)-octahydroindole-2-carboximidic acid

n-(4-carbamimidamidobutyl)-1-(2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl)-6-(sulfooxy)-octahydroindole-2-carboximidic acid

C29H46N6O9S (654.3047)


   

(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2s)-2-methylbutanoate

(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2s)-2-methylbutanoate

C36H46O11 (654.304)


   

4,5-dihydroxy-6-{2-hydroxy-3-[(14-methylpentadecyl)oxy]propoxy}-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

4,5-dihydroxy-6-{2-hydroxy-3-[(14-methylpentadecyl)oxy]propoxy}-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

C31H58O14 (654.3826)


   

(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate

(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate

C36H46O11 (654.304)


   

(6r)-16-[(2r,5s,6s)-5-(dimethylamino)-6-methyloxan-2-yl]-8-{[(2s,5s,6s)-5-(dimethylamino)-6-methyloxan-2-yl]oxy}-6,15-dihydroxy-6-methyl-2,11-dioxahexacyclo[10.8.0.0¹,³.0³,⁸.0¹⁰,¹².0¹⁴,¹⁹]icosa-14(19),15,17-triene-4,13,20-trione

(6r)-16-[(2r,5s,6s)-5-(dimethylamino)-6-methyloxan-2-yl]-8-{[(2s,5s,6s)-5-(dimethylamino)-6-methyloxan-2-yl]oxy}-6,15-dihydroxy-6-methyl-2,11-dioxahexacyclo[10.8.0.0¹,³.0³,⁸.0¹⁰,¹².0¹⁴,¹⁹]icosa-14(19),15,17-triene-4,13,20-trione

C35H46N2O10 (654.3152)


   

2-[4,9,14-trihydroxy-14-(methoxymethyl)-3,10-dimethyl-8-[(3,4,5-trihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl)oxy]tricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

2-[4,9,14-trihydroxy-14-(methoxymethyl)-3,10-dimethyl-8-[(3,4,5-trihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl)oxy]tricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

C34H54O12 (654.3615)


   

1'-o-palmitoyl-3'-o-(6-o-α-d-galactopyranosyl-β-d-galactopyranosyl)glycerol

NA

C31H58O14 (654.3826)


{"Ingredient_id": "HBIN002926","Ingredient_name": "1'-o-palmitoyl-3'-o-(6-o-\u03b1-d-galactopyranosyl-\u03b2-d-galactopyranosyl)glycerol","Alias": "NA","Ingredient_formula": "C31H58O14","Ingredient_Smile": "CCCCCCCCCCCCCCCC(=O)OCC(COC1C(C(C(C(O1)COC2C(C(C(C(O2)CO)O)O)O)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16552","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

3- o -acetylohchinolal

NA

C36H46O11 (654.304)


{"Ingredient_id": "HBIN009031","Ingredient_name": "3- o -acetylohchinolal","Alias": "NA","Ingredient_formula": "C36H46O11","Ingredient_Smile": "CC=C(C)C(=O)OC1CC(C(C2C1(C(C3(C(C2OC(=O)C)OC4C3=C(C(C4)C5=COC=C5)C)C)CC(=O)OC)C)(C)C=O)OC(=O)C","Ingredient_weight": "654.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8515","PubChem_id": "101938464","DrugBank_id": "NA"}

   

(1s,2r,5s,7r,8r,10s,11s,14s,15s)-14-[(1r)-1-[(2r,4r,5r,6s)-4,5-dihydroxy-4,5-dimethyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]ethyl]-8,14-dihydroxy-2,15-dimethylpentacyclo[8.7.0.0²,⁷.0⁵,⁷.0¹¹,¹⁵]heptadecan-3-one

(1s,2r,5s,7r,8r,10s,11s,14s,15s)-14-[(1r)-1-[(2r,4r,5r,6s)-4,5-dihydroxy-4,5-dimethyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]ethyl]-8,14-dihydroxy-2,15-dimethylpentacyclo[8.7.0.0²,⁷.0⁵,⁷.0¹¹,¹⁵]heptadecan-3-one

C34H54O12 (654.3615)


   

n-[(3r,4s,7s,10r,15as)-5,8-dihydroxy-7,10-bis(1h-indol-3-ylmethyl)-3-methyl-1,11-dioxo-3h,4h,7h,10h,13h,14h,15h,15ah-pyrrolo[2,1-c]1-oxa-4,7,10-triazacyclotridecan-4-yl]-3-methylbutanimidic acid

n-[(3r,4s,7s,10r,15as)-5,8-dihydroxy-7,10-bis(1h-indol-3-ylmethyl)-3-methyl-1,11-dioxo-3h,4h,7h,10h,13h,14h,15h,15ah-pyrrolo[2,1-c]1-oxa-4,7,10-triazacyclotridecan-4-yl]-3-methylbutanimidic acid

C36H42N6O6 (654.3166)


   

16-[5-(dimethylamino)-6-methyloxan-2-yl]-8-{[5-(dimethylamino)-6-methyloxan-2-yl]oxy}-6,15-dihydroxy-6-methyl-2,11-dioxahexacyclo[10.8.0.0¹,³.0³,⁸.0¹⁰,¹².0¹⁴,¹⁹]icosa-14(19),15,17-triene-4,13,20-trione

16-[5-(dimethylamino)-6-methyloxan-2-yl]-8-{[5-(dimethylamino)-6-methyloxan-2-yl]oxy}-6,15-dihydroxy-6-methyl-2,11-dioxahexacyclo[10.8.0.0¹,³.0³,⁸.0¹⁰,¹².0¹⁴,¹⁹]icosa-14(19),15,17-triene-4,13,20-trione

C35H46N2O10 (654.3152)


   

(2s,3ar,6r,7ar)-n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

(2s,3ar,6r,7ar)-n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

C29H46N6O9S (654.3047)


   

(1s,2s,5r,6s,13s,14r,15r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2r)-2-methylbutanoate

(1s,2s,5r,6s,13s,14r,15r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2r)-2-methylbutanoate

C36H46O11 (654.304)


   

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e)-deca-2,4-dienoate

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e)-deca-2,4-dienoate

C37H50O10 (654.3404)


   

(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

C29H46N6O9S (654.3047)


   

(1s,2r,5r,6r,13r,14s,15s,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate

(1s,2r,5r,6r,13r,14s,15s,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate

C36H46O11 (654.304)


   

6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl 2-methylbutanoate

6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl 2-methylbutanoate

C36H46O11 (654.304)


   

6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl 2-methylbutanoate

6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl 2-methylbutanoate

C36H46O11 (654.304)


   

6,10,10,14,23,27,27,31-octamethyl-15,20,32-trioxanonacyclo[19.15.1.0²,¹⁹.0³,¹⁶.0⁵,¹⁴.0⁶,¹¹.0²²,³¹.0²³,²⁸.0³³,³⁷]heptatriaconta-1(36),2(19),3(16),4,17,33(37),34-heptaene-18,35,36-triol

6,10,10,14,23,27,27,31-octamethyl-15,20,32-trioxanonacyclo[19.15.1.0²,¹⁹.0³,¹⁶.0⁵,¹⁴.0⁶,¹¹.0²²,³¹.0²³,²⁸.0³³,³⁷]heptatriaconta-1(36),2(19),3(16),4,17,33(37),34-heptaene-18,35,36-triol

C42H54O6 (654.392)


   

(2s,3s,4r,5r,6s)-4,5-dihydroxy-6-[(2r)-2-hydroxy-3-[(14-methylpentadecyl)oxy]propoxy]-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

(2s,3s,4r,5r,6s)-4,5-dihydroxy-6-[(2r)-2-hydroxy-3-[(14-methylpentadecyl)oxy]propoxy]-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

C31H58O14 (654.3826)


   

(1s,2r)-2-{4-[(2s)-2-{2,6-dimethoxy-4-[(1e)-prop-1-en-1-yl]phenoxy}propyl]-2,6-dimethoxyphenoxy}-1-(3,4,5-trimethoxyphenyl)propyl acetate

(1s,2r)-2-{4-[(2s)-2-{2,6-dimethoxy-4-[(1e)-prop-1-en-1-yl]phenoxy}propyl]-2,6-dimethoxyphenoxy}-1-(3,4,5-trimethoxyphenyl)propyl acetate

C36H46O11 (654.304)


   

(2r)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl hexadecanoate

(2r)-2-hydroxy-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl hexadecanoate

C31H58O14 (654.3826)


   

2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl 2-methylbut-2-enoate

2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl 2-methylbut-2-enoate

C36H46O11 (654.304)


   

n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid

C29H46N6O9S (654.3047)


   

{8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

{8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C35H46N2O10 (654.3152)


   

[(1s,2r,3r,4s,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-4,8,9,16-tetrahydroxy-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

[(1s,2r,3r,4s,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-4,8,9,16-tetrahydroxy-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C35H46N2O10 (654.3152)


   

(2r,4's,5s,6s,8'r,10'e,13's,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-21',24'-dihydroxy-5,11',13',22'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-12'-yl 2-methylpropanoate

(2r,4's,5s,6s,8'r,10'e,13's,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-21',24'-dihydroxy-5,11',13',22'-tetramethyl-2'-oxo-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-12'-yl 2-methylpropanoate

C38H54O9 (654.3768)


   

(1s,2r,5r,6r,13r,14s,15s,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2s)-2-methylbutanoate

(1s,2r,5r,6r,13r,14s,15s,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2s)-2-methylbutanoate

C36H46O11 (654.304)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-17-[(3-methylbut-2-enoyl)oxy]-8-[(3r)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-17-[(3-methylbut-2-enoyl)oxy]-8-[(3r)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C37H50O10 (654.3404)


   

(3r,6s,9r,12s,15s)-6,9-dibenzyl-12-[(2r)-4-hydroxybutan-2-yl]-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

(3r,6s,9r,12s,15s)-6,9-dibenzyl-12-[(2r)-4-hydroxybutan-2-yl]-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

C32H42N6O9 (654.3013)


   

19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-12-[(2-methylbut-2-enoyl)oxy]-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-17-yl 2-methylbut-2-enoate

19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-12-[(2-methylbut-2-enoyl)oxy]-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-17-yl 2-methylbut-2-enoate

C37H50O10 (654.3404)


   

(3s,6s,9s,12s,15s)-6,9-dibenzyl-12-[(2r)-4-hydroxybutan-2-yl]-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

(3s,6s,9s,12s,15s)-6,9-dibenzyl-12-[(2r)-4-hydroxybutan-2-yl]-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

C32H42N6O9 (654.3013)


   

(1r,2r,4r,5r,6s,7s,9r,10s,11s,12s,13s,14s,15r,22r,23r,25r)-10,11,22-trihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-12-yl benzoate

(1r,2r,4r,5r,6s,7s,9r,10s,11s,12s,13s,14s,15r,22r,23r,25r)-10,11,22-trihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-12-yl benzoate

C37H50O10 (654.3404)


   

2-({[1-(2-{[2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-5-carbamimidamidopentanoic acid

2-({[1-(2-{[2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-5-carbamimidamidopentanoic acid

C32H42N6O9 (654.3013)


   

6,9-dibenzyl-12-(4-hydroxybutan-2-yl)-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

6,9-dibenzyl-12-(4-hydroxybutan-2-yl)-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

C32H42N6O9 (654.3013)


   

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl hexadecanoate

2-hydroxy-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}propyl hexadecanoate

C31H58O14 (654.3826)


   

methyl (4s,4as,11br)-9-[(4r,4ar,6ar,7s,11as,11br)-4-(methoxycarbonyl)-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-7-yl]-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h-phenanthro[3,2-b]furan-4-carboxylate

methyl (4s,4as,11br)-9-[(4r,4ar,6ar,7s,11as,11br)-4-(methoxycarbonyl)-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-7-yl]-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h-phenanthro[3,2-b]furan-4-carboxylate

C42H54O6 (654.392)


   

(4s,5s,6s,11s,14s,21s,22s,23s,28s,31s)-6,10,10,14,23,27,27,31-octamethyl-15,20,32,38-tetraoxadecacyclo[19.15.1.1⁴,³⁶.0²,¹⁹.0³,¹⁶.0⁵,¹⁴.0⁶,¹¹.0²²,³¹.0²³,²⁸.0³³,³⁷]octatriaconta-1(37),2,16,18,33,35-hexaene-18,35-diol

(4s,5s,6s,11s,14s,21s,22s,23s,28s,31s)-6,10,10,14,23,27,27,31-octamethyl-15,20,32,38-tetraoxadecacyclo[19.15.1.1⁴,³⁶.0²,¹⁹.0³,¹⁶.0⁵,¹⁴.0⁶,¹¹.0²²,³¹.0²³,²⁸.0³³,³⁷]octatriaconta-1(37),2,16,18,33,35-hexaene-18,35-diol

C42H54O6 (654.392)


   

6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl 2-methylbutanoate

6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl 2-methylbutanoate

C36H46O11 (654.304)


   

2-[4-(2-{2,6-dimethoxy-4-[(1e)-prop-1-en-1-yl]phenoxy}propyl)-2,6-dimethoxyphenoxy]-1-(3,4,5-trimethoxyphenyl)propyl acetate

2-[4-(2-{2,6-dimethoxy-4-[(1e)-prop-1-en-1-yl]phenoxy}propyl)-2,6-dimethoxyphenoxy]-1-(3,4,5-trimethoxyphenyl)propyl acetate

C36H46O11 (654.304)


   

4-[(2-amino-1-hydroxy-3-methylpentylidene)amino]-4-({1-[(1-{[2-hydroxy-1-(c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}-2-phenylethyl)-c-hydroxycarbonimidoyl]-2-phenylethyl}-c-hydroxycarbonimidoyl)butanoic acid

4-[(2-amino-1-hydroxy-3-methylpentylidene)amino]-4-({1-[(1-{[2-hydroxy-1-(c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}-2-phenylethyl)-c-hydroxycarbonimidoyl]-2-phenylethyl}-c-hydroxycarbonimidoyl)butanoic acid

C33H46N6O8 (654.3377)


   

methyl 9-[4-(methoxycarbonyl)-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-7-yl]-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h-phenanthro[3,2-b]furan-4-carboxylate

methyl 9-[4-(methoxycarbonyl)-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-7-yl]-4,7,11b-trimethyl-1h,2h,3h,4ah,5h,6h-phenanthro[3,2-b]furan-4-carboxylate

C42H54O6 (654.392)


   

{11-ethyl-4,8,9,16-tetrahydroxy-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

{11-ethyl-4,8,9,16-tetrahydroxy-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C35H46N2O10 (654.3152)


   

(1r,2r,3r,4s,5s,7r,8r,9r,10r,11s,13s,15r)-2,4-bis(acetyloxy)-8,16-dihydroxy-5,9,12,12-tetramethyl-15-{[(2e)-2-methylbut-2-enoyl]oxy}-17-oxapentacyclo[7.6.2.0¹,¹⁰.0³,⁷.0¹¹,¹³]heptadecan-7-yl benzoate

(1r,2r,3r,4s,5s,7r,8r,9r,10r,11s,13s,15r)-2,4-bis(acetyloxy)-8,16-dihydroxy-5,9,12,12-tetramethyl-15-{[(2e)-2-methylbut-2-enoyl]oxy}-17-oxapentacyclo[7.6.2.0¹,¹⁰.0³,⁷.0¹¹,¹³]heptadecan-7-yl benzoate

C36H46O11 (654.304)


   

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-17-{[(2e)-2-methylbut-2-enoyl]oxy}-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-17-{[(2e)-2-methylbut-2-enoyl]oxy}-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C37H50O10 (654.3404)


   

(1r,2s,5s,6r,13r,14r,15s,17s,18r)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate

(1r,2s,5s,6r,13r,14r,15s,17s,18r)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate

C36H46O11 (654.304)


   

(1r,2r,4s,5r,6s,7s,9r,10s,11s,12s,13s,14s,15s,22r,25r)-10,11,22-trihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-12-yl benzoate

(1r,2r,4s,5r,6s,7s,9r,10s,11s,12s,13s,14s,15s,22r,25r)-10,11,22-trihydroxy-9-(hydroxymethyl)-2,13,15-trimethyl-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-12-yl benzoate

C37H50O10 (654.3404)


   

(3s,6r,12s,15s)-6,9-dibenzyl-12-[(2s)-4-hydroxybutan-2-yl]-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

(3s,6r,12s,15s)-6,9-dibenzyl-12-[(2s)-4-hydroxybutan-2-yl]-3,15-bis(hydroxymethyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

C32H42N6O9 (654.3013)


   

(1s,2s,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-2-methylbut-2-enoate

(1s,2s,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-2-methylbut-2-enoate

C36H46O11 (654.304)


   

(4s)-4-{[(2s,3s)-2-amino-1-hydroxy-3-methylpentylidene]amino}-4-{[(1s)-1-{[(1s)-1-{[(1s,2r)-2-hydroxy-1-(c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}-2-phenylethyl]-c-hydroxycarbonimidoyl}-2-phenylethyl]-c-hydroxycarbonimidoyl}butanoic acid

(4s)-4-{[(2s,3s)-2-amino-1-hydroxy-3-methylpentylidene]amino}-4-{[(1s)-1-{[(1s)-1-{[(1s,2r)-2-hydroxy-1-(c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}-2-phenylethyl]-c-hydroxycarbonimidoyl}-2-phenylethyl]-c-hydroxycarbonimidoyl}butanoic acid

C33H46N6O8 (654.3377)


   

9-{14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl}-7,8-dimethoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6,8,10-tetraen-18-one

9-{14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl}-7,8-dimethoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6,8,10-tetraen-18-one

C37H42N4O7 (654.3053)


   

2-{9-[3-(dimethoxymethyl)-6-(2-hydroxypropan-2-yl)oxan-2-yl]-3,7-dimethylnona-2,6-dien-1-yl}-2,4,6,9-tetrahydroxy-5,7-dimethylphenalene-1,3-dione

2-{9-[3-(dimethoxymethyl)-6-(2-hydroxypropan-2-yl)oxan-2-yl]-3,7-dimethylnona-2,6-dien-1-yl}-2,4,6,9-tetrahydroxy-5,7-dimethylphenalene-1,3-dione

C37H50O10 (654.3404)


   

2-(4-{2-[2,6-dimethoxy-4-(prop-1-en-1-yl)phenoxy]propyl}-2,6-dimethoxyphenoxy)-1-(3,4,5-trimethoxyphenyl)propyl acetate

2-(4-{2-[2,6-dimethoxy-4-(prop-1-en-1-yl)phenoxy]propyl}-2,6-dimethoxyphenoxy)-1-(3,4,5-trimethoxyphenyl)propyl acetate

C36H46O11 (654.304)


   

(2s)-2-[(1e,3r,4s,8r,9r,10r,11s,14r)-4,9,14-trihydroxy-14-(methoxymethyl)-3,10-dimethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}tricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

(2s)-2-[(1e,3r,4s,8r,9r,10r,11s,14r)-4,9,14-trihydroxy-14-(methoxymethyl)-3,10-dimethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-{[(2-methylbut-3-en-2-yl)oxy]methyl}oxan-2-yl]oxy}tricyclo[9.3.0.0³,⁷]tetradeca-1,6-dien-6-yl]propyl acetate

C34H54O12 (654.3615)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-17-{[(2e)-2-methylbut-2-enoyl]oxy}-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-19-hydroxy-4-methoxy-1,9,11,16-tetramethyl-17-{[(2e)-2-methylbut-2-enoyl]oxy}-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C37H50O10 (654.3404)


   

(1s,4r,12r,16s)-9-[(5r,9r,16r)-14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl]-7,8-dimethoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6,8,10-tetraen-18-one

(1s,4r,12r,16s)-9-[(5r,9r,16r)-14,16-dihydroxy-6-methyl-2-oxo-1,6-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl]-7,8-dimethoxy-5-methyl-17-oxa-5,15-diazahexacyclo[13.4.3.0¹,¹⁶.0⁴,¹².0⁶,¹¹.0¹²,¹⁶]docosa-2,6,8,10-tetraen-18-one

C37H42N4O7 (654.3053)


   

(2s)-2-[(2e,6e)-9-[3-(dimethoxymethyl)-6-(2-hydroxypropan-2-yl)oxan-2-yl]-3,7-dimethylnona-2,6-dien-1-yl]-2,4,6,9-tetrahydroxy-5,7-dimethylphenalene-1,3-dione

(2s)-2-[(2e,6e)-9-[3-(dimethoxymethyl)-6-(2-hydroxypropan-2-yl)oxan-2-yl]-3,7-dimethylnona-2,6-dien-1-yl]-2,4,6,9-tetrahydroxy-5,7-dimethylphenalene-1,3-dione

C37H50O10 (654.3404)


   

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e)-deca-2,4-dienoate

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e)-deca-2,4-dienoate

C37H50O10 (654.3404)